drugset

drugset / Trial / NCT00209937

A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia

NCT00209937 ↗

Phase 3 Completed 675 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia

Timeline

Start: 2003-01
Primary completion: —
Completion: 2004-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	gaboxadol	Small molecule	—	—

Indications